During the development of a dermal drug, much efforts tend to be placed on improving its delivery through skin. These efforts are driven by the known risk of not engaging the target. Indeed to increase comfort that the target will be engaged one need to try fullfill as best as it can evidence of sufficient compound on board for a desired time (i.e., PK within skin) and demonstration of pharmacological activity.

Book – Dermal Drug Selection and Development